Saturday 17 October 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 53.1%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.78
0.65
−5.69%
Follow BHVN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 5.42 | 12.35 | 26.80 | 7.48 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 17.86 | 44.29 | 62.21 | 44.28 | |||||
| People | |||||||||||||||
| People | Employees | 12 | 42 | 63 | 647 | 825 | 928 | 202 | 239 | 256 | 274 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (0.11) | (0.30) | 0.00 | — | — | — | |||||
| EBT | (63) | (126) | (240) | (528) | (119) | (212) | (570) | (410) | (846) | (737) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (64) | (127) | (241) | (529) | (119) | (214) | (570) | (408) | (846) | (739) | |||||
| Depreciation | 0 | — | 4 | 1 | 0 | 1 | 1 | 7 | 8 | 10 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (5.04) | (5.00) | (6.15) | (10.91) | (3.01) | (5.43) | (12.75) | (5.73) | (9.28) | (6.86) | |||||
| Cash flow | (2.34) | (3.40) | (5.03) | (7.78) | (1.93) | (3.70) | (6.65) | (4.66) | (6.38) | (5.66) | |||||
| Capex | 0.00 | (0.02) | (0.11) | (0.08) | (1.12) | (0.02) | (0.14) | (0.04) | (0.04) | (0.01) | |||||
| Free cash flow | (2.34) | (3.42) | (5.14) | (7.86) | (3.05) | (3.73) | (6.79) | (4.70) | (6.42) | (5.67) | |||||
| Book value | (0.14) | 4.74 | 3.85 | (0.15) | (9.96) | 0.88 | 12.04 | 6.01 | 4.64 | 0.48 | |||||
| Shares, m | 13 | 28 | 39 | 48 | 39 | 39 | 45 | 71 | 91 | 108 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | — | — | — | — | ||||
| P/S | — | — | — | — | 53.04 | 9.07 | — | — | — | — | |||||
| P/B | — | — | — | — | 0.00 | 156.42 | — | — | — | — | |||||
| EV/Sales | — | — | — | — | 52.75 | 10.14 | — | — | — | — | |||||
| EV/FCF | — | — | — | — | (27.93) | (36.22) | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (30) | (95) | (197) | (377) | (76) | (146) | (298) | (332) | (582) | (609) | ||||
| Capex | 0 | (1) | (4) | (4) | (44) | (1) | (6) | (3) | (4) | (1) | |||||
| Free cash flow | (30) | (95) | (201) | (381) | (120) | (147) | (304) | (335) | (586) | (610) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 16 | 127 | 253 | 262 | 326 | 53 | 497 | 387 | 384 | 252 | ||||
| Total debt | 1 | — | 118 | 248 | 267 | 3 | 31 | — | — | 239 | |||||
| Net debt | (23) | (131) | (146) | (69) | (88) | (73) | (470) | (382) | (486) | (80) | |||||
| Shareholders’ equity | (2) | 132 | 151 | (7) | (392) | 35 | 539 | 428 | 423 | 52 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (440.53) | (160.08) | (110.29) | (166.74) | (23.01) | (51.58) | (141.89) | (69.48) | (150.03) | (138.54) | ||||
| ROIC | 0.00 | (13,367.54) | (3,004.63) | 0.00 | 0.00 | 0.00 | (515.93) | (590.46) | 0.00 | 0.00 | |||||
| ROE | 289.80 | (320.22) | (170.33) | (737.03) | 59.39 | 119.61 | (198.89) | (84.44) | (198.83) | (310.75) | |||||
Negative figures in brackets.
Latest quarter Jun 2021
Charts ten years each
Biohaven Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MESO Mesoblast Limited | $1.8B | — (loss-making) | — | −13.41% (below 0%: shrinking) | n/m | −89.23% (below 0%: shrinking) | (353.35%) | (909.40%) | Compare |
| URGN Urogen Pharma | $1.8B | — (loss-making) | — (loss-making) | +199.22% (above 0%: growing) | n/m | +17.26% (above 0%: growing) | 90.93% | 0.15% | Compare |
| XNCR Xencor, Inc. | $1.8B | — (loss-making) | — (loss-making) | +17.46% (above 0%: growing) | n/m | −52.91% (below 0%: shrinking) | 100.00% | (72.37%) | Compare |
| VIR Vir Biotechnology, Inc. | $1.8B | — (loss-making) | — (loss-making) | +19,582.54% (above 0%: growing) | n/m | +200.47% (above 0%: growing) | 100.00% | 30.75% | Compare |
| SEPN Septerna, Inc. | $1.8B | — (loss-making) | — (loss-making) | +22,375.63% (above 0%: growing) | n/m | −9.01% (below 0%: shrinking) | 100.00% | (62.95%) | Compare |
| BHVN Biohaven Ltd. | $1.7B | — (loss-making) | — (loss-making) | +131.43% (above 0%: growing) | n/m | +49.13% (above 0%: growing) | 0.00% | 0.00% | |
| TRVI Trevi Therapeutics, Inc. | $1.7B | — (loss-making) | — | — | n/m | −73.77% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NUVB Nuvation Bio Inc. | $1.7B | — (loss-making) | — (loss-making) | +555.64% (above 0%: growing) | n/m | +10.62% (above 0%: growing) | 70.11% | (161.06%) | Compare |
| ZBIO Zenas BioPharma, Inc. | $1.7B | — (loss-making) | — (loss-making) | — | n/m | −37.12% (below 0%: shrinking) | 100.00% | (10,765.90%) | Compare |
| Median of peers | $1.8B | — | — | +377.43% | — | −23.06% | 95.47% | (67.66%) |
Biohaven Ltd. (BHVN) key facts
- Biohaven Ltd. (BHVN) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, BHVN traded at $10.78, a market capitalization of $1.7 billion.
- Return on equity was −310.8% and debt-to-equity 21.23.
Biohaven Ltd. (BHVN) Latest News
No news at this impact. Lower the threshold for more.